{
    "nct_id": "NCT05150691",
    "official_title": "A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1303/BNT323 in Patients With Advanced/Metastatic Solid Tumors",
    "inclusion_criteria": "* Has a pathologically documented HER2-positive or HER2-expressing (except for cohort 2h where the requirement is HER2-null), advanced/unresectable, recurrent, or metastatic malignant solid tumor that is refractory to or intolerable with standard treatment, or for which no standard treatment is available.\n* At least 1 measurable lesion (per RECIST 1.1)\n* Provide signed informed consent\n* ECOG performance status (PS) of 0-1.\n* LVEF ≥ 50% by ECHO or MUGA\n* Adequate organ functions\n* Provide pre-existing diagnosis of HER2 status or resected tumor samples or undergo fresh tumor biopsy for HER2 testing.\n* Life expectancy of ≥ 3 months.\n\nAdditional Inclusion Criteria for Part 2 Expansion Group 9:\n\n1. Has pathologically documented advanced/unresectable, recurrent, or metastatic EC (including UCS and USPC) and has progressed on or after at least 1 line of systemic treatment including platinum-based therapy and exposure to ICI but no more than prior 3 lines of therapy for advanced/unresectable, or metastatic disease. Note: endocrine therapy will not qualify as a systemic therapy line.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* History of symptomatic CHF (New York Heart Association [NYHA] classes II-IV) or serious cardiac arrhythmia requiring treatment.\n* History of myocardial infarction or unstable angina within 6 months before Day 1.\n* Average QTcF > 450 ms in males and > 470 ms in females\n* History of clinically significant lung diseases\n* Uncontrolled infection requiring IV antibiotics, antivirals, or antifungals.\n* HIV infection with AIDS defining illness or active viral hepatitis.\n* Clinically active brain metastases\n* Unresolved toxicities from previous anticancer therapy, defined as toxicities not yet resolved to NCI-CTCAE version 5.0, Grade ≤ 1 or baseline.\n* A known hypersensitivity to either the drug substances or inactive ingredients in the drug product.\n* Part 2 (expansion) Only:Multiple primary malignancies within 3 years, except adequately resected non- melanoma skin cancer, curatively treated in-situ disease, other solid tumors curatively treated, or contralateral breast cancer.",
    "miscellaneous_criteria": ""
}